Zou, T.; Liu, J.-Y.; Qin, Q.; Guo, J.; Zhou, W.-Z.; Li, X.-P.; Zhou, H.-H.; Chen, J.; Liu, Z.-Q. Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Biomedicines2023, 11, 3133.
Zou, T.; Liu, J.-Y.; Qin, Q.; Guo, J.; Zhou, W.-Z.; Li, X.-P.; Zhou, H.-H.; Chen, J.; Liu, Z.-Q. Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Biomedicines 2023, 11, 3133.
Zou, T.; Liu, J.-Y.; Qin, Q.; Guo, J.; Zhou, W.-Z.; Li, X.-P.; Zhou, H.-H.; Chen, J.; Liu, Z.-Q. Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Biomedicines2023, 11, 3133.
Zou, T.; Liu, J.-Y.; Qin, Q.; Guo, J.; Zhou, W.-Z.; Li, X.-P.; Zhou, H.-H.; Chen, J.; Liu, Z.-Q. Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Biomedicines 2023, 11, 3133.
Abstract
Background: Lung cancer is still the most lethal malignancy in the world from the report of Cancer Statistics in 2021. Platinum-based chemotherapy combined immunotherapy is the first-line treatment in lung cancer patients. However, the 5-year survival rate always affected by the adverse reaction and drug resistance caused by platinum-based chemotherapy. DNA damage and repair system is one of the important mechanisms which can affect the response to chemotherapy and clinical outcome in lung cancer patients.
Objective: The objective of this study is to find the relationship between the polymorphisms of DNA repair genes with the prognosis in platinum-based chemotherapy in lung cancer patients.
Patients and Methods: We performed genotyping in 17 single nucleotide polymorphisms (SNPs) of Excision Repair Cross-Complementation group (ERCC) genes and X-ray Repair Cross-Complementing (XRCC) genes of 345 lung cancer patients by Sequenom MassARRAY. We used Cox proportional hazard models, state and plink to analyze the associations between SNPs and the prognosis of lung cancer patients.
Results: We found that the ERCC5 rs873601 was associated with the overall survival time in lung cancer patients treat by platinum-based chemotherapy (p=0.031*). We also discovered that the polymorphisms in rs873601 was significantly associated with the prognosis in age more than 55 years, Small Cell Lung Cancer (SCLC) and smoking patients, Long Intergenic Non-protein Coding RNA (PNKY) rs2444933 in age less than 55 years, SCLC, metastasis and stage III/IV/ED patients, Short Tau Inversion Recovery (STIR1) rs3740051 in SCLC and metastasis patients, PNKY rs1869641 in SCLC patients, XRCC5 rs1051685 in non-metastasis patients, respectively.
Conclusion: The ERCC5 rs873601(G>A) maybe a valuable biomarker for predicting the prognosis in lung cancer patients treated with platinum-based chemotherapy.
Statements and Declarations: The authors declare that they have no conflict of interest.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
